NEW YORK (GenomeWeb News) - Caprion Pharmaceuticals has withdrawn its initial public offering due to “adverse market conditions,” the company said today.
 
Drug makers use the company’s CellCarta product, a proteomics technology, to profile proteins in solid tissues and plasma for disease-target identification and predictive medicine.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

Researchers link genetic links between education and smoking and longevity.

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.